Bexarotene-Induced Hypertriglyceridemia: A Case Report.

Article Details

Citation Copy to clipboard

Maminakis C, Whitman AC, Islam N

Bexarotene-Induced Hypertriglyceridemia: A Case Report.

Case Rep Oncol. 2018 Apr 11;11(1):234-238. doi: 10.1159/000488447. eCollection 2018 Jan-Apr.

PubMed ID

29805374 [ View in PubMed

]

Abstract

We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m(2) due to progressing disease. The patient experienced good clinical response, but unfortunately, she developed rapid and profound hypertriglyceridemia. Although hypertriglyceridemia occurs in high incidence with bexarotene therapy, management recommendations are scarce. Due to the rise in triglycerides, atorvastatin 10 mg daily was initiated in combination with fenofibrate 120 mg daily. Triglycerides continued to increase, so the patient was instructed to take atorvastatin 40 mg, fenofibrate 120 mg, and to hold bexarotene for 2 weeks. After the 2-week break, bexarotene was restarted at 150 mg/m(2).

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Bexarotene	Cytochrome P450 3A4	Protein	Humans	Unknown	Substrate Inducer	Details

Drug Interactions

Drugs	Interaction
Integrate drug-drug interactions in your software
Bexarotene Vitamin A	The risk or severity of adverse effects can be increased when Vitamin A is combined with Bexarotene.